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Summary
Erythrocytes (E) lacking high incidence blood group antigens were screened by an antiglobulin
test with a monoclonal antibody to human complement receptor type 1 (CR1 ; C3b/C4b receptor;
CD35) . Some examples of E lacking Knops, McCoy, Swain-Langley, and York antigens, a
serologically related group, were not agglutinated . Moreover, E of the null phenotype for these
same antigens were nonreactive. To further explore this relationship, E expressing these antigens
were surface labeled, solubilized, and incubated with the corresponding blood group-specific
antisera . CR1 was immunoprecipitated, indicating that the epitopes recognized by each of these
antisera are expressed on CR1 .
E of two individuals, putative null phenotypes for the Knops, McCoy, and Swain-Langley
blood group antigens, expressed a very low number ofCRI (<30/E ; -10% ofthe normal mean) .
This observation accounts for their lack of reactivity in the antiglobulin test and their prior
designation as null phenotypes . Also, the previously reported low as well as variable expression
ofCR1 on E explains prior difficulties in the serologic analyses of these blood group antigens .
Complement receptor type 1 (CR1 ; C3b/C4b receptor;
CD35) is expressed on human erythrocytes (E)t and
leukocytes (1, 2) . Immune adherence, the attachment of
C3b/C4b-bearingimmune complexes to primate E or non-
primate platelets, is mediated by this receptor as part of its
role in the metabolism ofimmune complexes (3) . In 1980,
Fearon (4) purified CR1, and subsequent studies by Wong
et al . (5) and Dykman et al . (6-8) led to the discovery of
an unusual size polymorphism ofthis receptor. Four codomi-
nantly inherited allelic size variants with M, of 190,000,
220,000, 250,000 and 280,000 were identified (9) . Subsequent
biochemical and molecular characterization of the variants
suggested that a highly homologous repeating unit was dupli-
cated or deleted (reviewed in references 1 and 2) . Further,
these investigations pointed out that the structural gene for
CRI was not linked to HLA (10), as had been initially pro-
posed (11, 12), and also led to the discovery of anew linkage
group at 1g32 of complement regulatory and receptor pro-
teins (13, 14) .
In 1975, Rothman et al . (3) analyzed E ofindividuals lacking
common blood group antigens by immune adherence . One
individual was immune adherence negative and had a rare
blood group phenotype, Rh null ; however, other individuals
of this phenotype were immune adherence positive. In the
early 1980s, two of us (J . P Atkinson, J. J . Moulds) unsuc-
cessfully attempted to find a blood group system with allelic
frequencies that paralleled those ofthe CRI polymorphic size
variants . In the present studies, screening of E negative for
high frequency blood group antigens with a mAb to CR1
led to the identification of CR1 as a blood group antigen
and multiplenew alleles that encode protein polymorphisms
of CR1 .
Materials and Methods
Antisera.
￿
The following antibodies toCRI were used: a rabbit
polyclonal antiserum, provided by E . Medof (Case Western Re-
serve University, Cleveland, OH), and mousemAbs Ell, provided
by N . Hogg (ICRF Laboratories, London, England), and 3139,
provided by E . Brown (Washington University School of Medi-
cine, St . Louis, MO) . Blood group antisera, stimulated by trans-
fusion or pregnancy, were obtained from patient samples refer-
red to the consultation laboratory of Gamma Biologicals Inc .,
Houston, TX . The antisera designated "Kn/McC" belong to a
heterogeneous group related to Knops and McCoy due to their
lack of reactivity with the null phenotype MH .
Serological Testing.
￿
The anti-CRI mAbs were tested against E
lacking multiple antigens in a known blood group system or those
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obtained through the "Serum, Cells, and Rare Fluid (SCARF) Ex-
change" were storedin liquid nitrogen until tested . ThemAbs were
diluted 1:500 in PBS containing 8% BSA for use in a mouse an-
tiglobulin technique (15) .
Fresh or frozen E from selected individuals were serologically
phenotyped for the "Knops-McCoy" ("Kn/McC"), Knops (Kn),
McCoy (McC), Swain-Langley (SI), York (Yk), and Cost (Cs) an-
tigens. Saline-suspendedE were incubatedwith the appropriate an-
tisera for 1 h at 37°C followed by a standard antiglobulin proce-
dure (15) .
Immunoprecipitation and Affinity Chromatography.
￿
Immunopre-
cipitation, affinity chromatography, and SDS-PAGE followed by
autoradiography were performed as described (6) . E were surface
labeled with 1N by a modified lactoperoxidase-glucose oxidase
method (6) .
ELISA .
￿
mAbs were purified by ammonium sulfate precipita-
tion . Microtiter wells (MaxiSorp ; Nunc, Roskilde, Denmark) were
coated with 2.51~g/ml of3D9, the capturemAb. Horseradish per-
oxidase (Boehringer Mannheim Biochemicals, Indianapolis, IN)-
conjugated Ell, the detection mAb, was prepared by a modification
of the procedure of Nakane and Kawaoi (16) . After a 2-h incuba-
tion at 37°C with the conjugated Ell (10 ng/ml), color was devel-
oped with o-phenylenediamine and the absorbance was read at
490 nm in a microplate reader (Dynatech, Chantilly, VA). Samples
were referenced relative to a standardized preparation of E ghosts
of known CRI number (9) and to purified CRI (17) .
Results
Identification by Hemagglutination of Blood Group Antigens
Related to CR1. E negative for high frequency blood group
antigens were tested by agglutination with a mAb to CRl
(Table 1). Initially, one example each ofRh null, Jk-3, i adult,
Lan-, "Kn/Mc"-, Sla-, Yk'-, and Yk'-/Cs'- was nonreactive .
A second example of Rh null, Jk-3, i adult, and Lan- was
reactive. These blood groups were not investigated further
since they had no apparent relationship to one another and
because biochemical data indicate that they could not beCRI
(18). However, additional examples ofE negative for the related
antigens "Kn/McC"; Sl', and Yk° gave variable reactions, in-
cluding negative ones. Moreover, E fromMH, the null pheno-
type for "Kn/McC", Kn°, McC', and S1 1 , were not agglu-
tinated . Because of these results and the known serologic
relationship between Kn', McC', and Yk , (19), E expressing
these antigens were investigated further by immunoprecipi-
tation.
Knops, McCoy, Swain-Langley, and York Blood Group-specific
Antisera Immunoprecipitate CRI . Antisera that reacted with
the "Kn/McC", Kn-, McC', Sla, or Yk' blood group an-
tigens were incubated with 125I-surface-labeled, solubilized
E . Multiple examples of each of these antisera precipitated
a 220-kD protein that aligned with thecommon polymorphic
size variant of CRl (Fig. 1 A) . In most experiments CRI
was the onlylabeled band identified and, in those cases where
another band was noted, it was also present in control (normal
serum) lanes.
Further evidence that these blood group antigens are present
on CR1 included the following : (a) the protein precipitated
by these antisera had anMr of 190,000 under nonreducing
1160
￿
Complement Receptor Type 1-related Blood Group Antigens
Figure 1 . Blood group-specific antisera (Kn', McCa, Yka, Sla, and
"Kn/McC") immunoprecipitate CR1 . (A) In this and subsequent Figures,
1151-surfaced-labeled, detergent-solubilized E preparations are the starting
material . E ofa homozygous donor expressing the common CRI pheno-
type were assessed by affinity chromatography with iC3-Sepharose (lane
1) or by immunoprecipitation (lanes 2-7) . E ofa heterozygous donor ex-
pressing the two most common polymorphic size variants of CRI (lanes
8-I1) were similarly analyzed. For immunoprecipitation, amAb to CR1,
3D9 (lane 2) or Ell (lane 9), and the blood group-specific antisera (lanes
4-7 and 9-11) were used. A normal human serum was used as a control
(lane 3) . The relatively weak reaction with the anti-Kn' antisera (lane 4)
is likely due to its low titer (1:2 vs . 1:64 or greater for the others) . These
and subsequent autoradiographs are of5% gels analyzed by SDS-PAGE
(reducing conditions) . (B) Comparison of the immunoprecipitated pro-
teins under reducing and nonreducing conditions . Experimental condi-
tions are as in A . Lanes 1-6 and 7-10 were analyzed on separate gels,
conditions (Fig . 1 B) and again aligned with CRl ; (b) the
antisera recognized the twocommon polymorphic size vari-
ants ofCRI (Fig . 1 A, lanes 9-11) ; (c) a protein corresponding
to CR1 was not precipitated by these antisera if solubilized
E preparations were absorbed with mAbs to CRl (Fig. 2) ;
and (d) sera of normal individuals (Fig . 1 A) and antisera
to other blood group antigens (data not shown) did not
precipitate CRl .
CRI Is Present onE of Antibody Producers.
￿
To assess if the
antibody producers represent a null phenotype or expressed
an anomalously migrating species ofCRl, labeled E of four
antibody producers (Kna, McC', "Kn/Mc", and Sla) were
analyzed by immunoprecipitation followed by SDS-PAGE and
autoradiography . In each case, their CRl had an identical
Mr to the common polymorphic size variant (data not
shown) .Figure 2 .
￿
mAbs to CR1 absorb the antigen recognized by the blood
group-specific antisera . CR1was immunoprecipitated from anE prepara-
tion by a mixture ofmAbs (E11 and3D9) toCR1 (lane 1) . ThisE prepa-
ration was then incubated with the blood group-specific antisera (lanes
2-4) . A threefold longer exposure of this gel (10 d) did not demonstrate
CRI in lanes 2-4 . The same result was obtained with an antiserum to
Kna (data not shown) . These same antisera precipitatedCRI in this and
other experiments (Fig. 1) fromE preparations that had not been precleared
of CRl .
The Null Phenotypes for the CRl-related Blood Group An-
tigens Express Low CopyNumber . TheE ofMH are the null
phenotype for the blood group antisera recognizing CR1 .
A second individual's E, LM, are the Rh null sample that
was nonreactive with Ell (Table 1) and those previously de-
scribed asimmune adherence negative (11) . LM'sE typed iden-
tically to the rare MH phenotype .
MH's andWsE were radiolabeled, solubilized, and then
incubated with antibodies to CR1 . CRI was immunopre-
cipitated in both cases and aligned with the common poly-
morphic CR1 size variant . Their CRl also bound iC3 (Fig .
3) . Densitometric analysis of these autoradiographs suggested
that E ofMH and LM expressed a low number ofCRl. An
ELISA was used to more quantitatively assess this observa-
tion . The range of CRl/E for 25 unrelated healthy donors
was 60-483 (mean, 300) while MH expressed 28 and LM
20 CRi/E . These results confirm the presence of CRl on
E ofMH and LM and provide an explanation, i.e., low copy
number, for the discrepancy between the negative results by
agglutination (Table 1) but positive results by immunopre-
cipitation (Fig. 3) .
To determine their correct phenotype, E ofMH and LM
were typed by immunoprecipitation with the same antisera
used in the agglutination assay. CR1 ofLM was precipitated
by antisera to Kna, McC', Sla, and Yk a . CR1 ofMH was
precipitated by antisera to McC' and Yka , but this analysis
was inconclusive using anti-Kna or anti-Sla .
Discussion
The goal of this study was to find a CRI-related blood
group system . The availability of mAbs to CRI provided
a tool to screen, by an antiglobulin assay, E deficient in blood
group antigens . Some examples ofE, lacking a related group,
"Kn/McC" ; Sla and Yka, were not agglutinated by a mAb
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Analysis ofE Lacking High Incidence Antigens
with an Agglutination Assay Using a Mouse mAb (Ell) to CRI
This table is divided into two parts. The"Null Phenotype" section refers
to E that are negative for several antigens in a blood group system . For
the remainder of the Table, E lacking a single high incidence antigen
are shown .
' - = negative, + = positive .
￿
indicates a group in which at
least one example was negative .
t Numbers in parentheses represent the number of samples evaluated .
The nonreactive Rh null sample is LM (see text) .
S Helgesen cells were stored in liquid nitrogen and thawed before test-
ing . Fresh Helgesen cells were tested within 48 h of obtaining the blood
sample .
to CRI. Further, E of the null phenotype (MH) for these
antigens were also nonreactive. These serologic results
prompted analysis of the alloantisera specific for these blood
group antigens . These antisera specifically precipitatedCRl ;
therefore, these blood group antigens are expressed on CRI .
Antisera to these CR1-related blood group antigens have
Null phenotype
Rx with
Ell"
High incidence
Antigen
Rx with
Ell
Ko + i (adult) (2) -/+
Oh + U- +
Rh null (2)t -/+ En'- +
Tj'- + Ge-1, -2, -3 +
Jk
3
(2) -/+ k- +
Leach + Kpb- +
Helgeson-frozens Jsb-
Helgeson-freshs Fy3
Lan- (2) -I+
Yt'- +
Vel-
Co'-
Lu (a-b-)
Aub-
Ok'-
Dr'-
At'-
Er'-
Rg- (C4AQO)
Ch- (C4BQO)
Hy-
Gy'-
JMH- (acquired)
JMH- (genetic)
"Kn/McC"- (2)
Sl'- (5) -l+
Yk'- (2)
Cs'- (2)
Yk'-/Cs'-(3)traditionally been placed in a collection referred to as high-
titer, low-avidity (HTLA) antibodies (19) . They are charac-
terized by their weak reactivity and wide variation in strength
of their agglutination reactions . The serological data indi-
cate that "Kn/McC", Kn', McC', Sl', and Yka define dis-
tinct but related blood group antigens (18, 20-22) . Thus,
the prior serological data and the present investigation have
led to the identification ofmany alleles that encodenew pro-
tein polymorphisms of CR1 .
Individuals lacking all Kn, McC, and Sl antigens by stan-
dard agglutination assays are said to express the "Helgeson
phenotype". MH was the first such example with this pat-
tern of reactivity (21) . Our results indicate that this lack of
reactivity in the agglutination assay forMH and another in-
dividual of the same phenotype (LM) is due to a low number
ofCR1/E (<30) . This explains why such E are nonreactive
in antiglobulin assays and their prior designation as a null
phenotype.
A characteristic of HTLA antibodies is a wide variation
in the strength of their agglutination reactions with E from
different individuals. This serologic observation is accounted
for by what is known about the expression of CR1 on E .
Thus, thenumber ofCR1 molecules/E vary from individual
to individual by >10-fold (23) . This variation of E/CR1 is
regulated in part in a Mendelian fashion and is associated with
a HindIII RFLP (23) . The presence (L or low allele; gene
frequency of 0.24) or absence (H or high allele; gene frequency
of 0.76) of a HindIII site in an intron in the COON-coding
halfofthe gene (24) correlates with CRl/E . This means that
-6% of the population are homozygous for expression of
a low CR1 copy number/E. The relative low expression of
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putative null phenotype for the Kn, McC, and SI blood
group antigens express CRl . CR1 was purified from E
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3-S and 8-10). In parallel, CR1 of E preparations of a
control individual was purified (lanes 1 and 6) .
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antigens, as well as the variability in expression between in-
dividuals, undoubtedly accounts for the difficulties experi-
enced by serologists using agglutination assays. It also ex-
plains the variable reactions we observed in the analysis of
E with a mAb to CRl by agglutination (Table 1) . For ex-
ample, some Sl'-, Yk°-, or Cs'- E samples were reactive
and others were nonreactive with amAb toCR1 . When these
E were tested with mAbs and the human blood group an-
tisera specific for CR1, a pattern of reactivity was observed
that was correlated with the number ofCR1/E (our unpub-
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dicated Yk' was a CR1-related blood group antigen, two
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First, three Cs'-specific antisera did not precipitate CR1 .
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number of CR1/E, including one of the null phenotypes (LM)
(our unpublished data) . Consequently, the serologic associa-
tion of Yk' and Cs' is not accounted for by our data .
While this work was in progress, an abstract by Rao et
al . (25) reported an association between CRl and the Knops-
McCoy group. In contrast to their conclusion that E of the
null phenotype (Helgeson) expressed no or a highly abnormal
form ofCR1, we found that this phenotype is characterized
by expression of a low number ofCRl, which has normal
molecular weight and binds iC3 . In addition, our results in-
dicate that Yk' is also expressed on CR1 .
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